Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pain, Postoperative 4Pain 3Neoplasms 3Breast Neoplasms 2Urinary Bladder Neoplasms 1Pneumonia 1Patient Satisfaction 1Paget Disease, Extramammary 1Operable Breast Cancer 1Myofascial Pain Syndromes 1Lymphoma, Follicular 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Chronic Pain 1Cancer Pain 1Agnosia 1

Interventions

Gemcitabine 28Cisplatin 26Mitomycin 18BCG Vaccine 12pembrolizumab 9Paclitaxel 8Doxorubicin 7Docetaxel 75-aminolevulinic acid hexyl ester 7apaziquone 6Carboplatin 6vinflunine 5enfortumab vedotin 5atezolizumab 5Vinblastine 5Radiotherapy 5Methotrexate 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cystectomy 5durvalumab 4Surgical Procedures, Operative 4Nivolumab 4Transurethral Resection of Bladder 3Specimen Handling 3Selenium 3Radiation 3Filgrastim 3Cystoscopy 3BCG Connaught 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Urinary Bladder Neoplasms × Lidocaine × Clear all
NCT06301308 2024-04-24

A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial

Second Xiangya Hospital of Central South University

Phase 3 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡